Published 2 days ago • loading... • Updated 2 hours ago
MSD Stops Trials of BTK Inhibitor for Blood Cancers
Merck said an independent monitoring committee found the drug’s benefits may not outweigh its risks, ending two other late-stage trials.
Summary by Pharmaphorum
9 Articles
9 Articles
Merck stops trials of blood cancer drug after review of risks
Coverage Details
Total News Sources9
Leaning Left0Leaning Right2Center2Last Updated50% Center, 50% Right
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
50% Right
C 50%
R 50%
Factuality
To view factuality data please Upgrade to Premium








